The Technical Analyst
Icosavax, Inc. [ICVX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Icosavax, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.91% $15.31
America/New_York / 16 feb 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 769.04 mill |
| EPS: | -2.20 |
| P/E: | -6.96 |
| Earnings Date: | Apr 04, 2024 |
| SharesOutstanding: | 50.23 mill |
| Avg Daily Volume: | 1.053 mill |
| RATING 2024-02-16 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.96 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.18x |
| Company: PE -6.96 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 15.10 - 15.52 ( +/- 1.36%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-19 | Ra Capital Management, L.p. | Sell | 638 668 | Common Stock |
| 2024-02-19 | Ra Capital Management, L.p. | Sell | 22 278 | Stock Option (Right to Buy) |
| 2024-02-19 | Ra Capital Management, L.p. | Sell | 17 000 | Stock Option (Right to Buy) |
| 2024-02-19 | Simpson Adam K. | Sell | 129 032 | Common Stock |
| 2024-02-19 | Simpson Adam K. | Sell | 191 449 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -94.08 |
| Last 100 transactions |
| Buy: 419 662 | Sell: 10 978 493 |
Forecast:
01:40 - $18.02
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.31 (-0.91% ) |
| Volume | 8.56 mill |
| Avg. Vol. | 1.053 mill |
| % of Avg. Vol | 812.39 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ICVX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:31 | sell | $15.31 | N/A | Active |
|---|
ICVX
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Latest Press Releases
2024-01-26 17:45:00 - Press Release
Icosavax Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Icosavax, Inc. - Icvx
New orleans , jan. 26, 2024 /prnewswire/ -- former attorney general of louisiana charles c. foti, jr., esq.
2024-01-03 14:20:00 - Press Release
Icvx Stock Alert: Halper Sadeh Llc Is Investigating Whether The Sale Of Icosavax, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of icosavax, inc. (nasdaq: icvx) to astrazeneca for $15.00 per share in cash plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, is fair to icosavax shareholders. the tender offer in connection with the proposed transaction is currently set to expire on or around january 26, 2024. halper sade.
2023-12-29 16:19:00 - Press Release
Icosavax Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Icosavax, Inc. - Icvx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of icosavax, inc. (nasdaqgs: icvx) to astrazeneca. under the terms of the proposed transaction, shareholders of icosavax will receive $15.00 in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, for.
2023-12-14 22:47:00 - Press Release
Icosavax Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Icosavax, Inc. - Icvx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of icosavax, inc. (nasdaqgs: icvx) to astrazeneca. under the terms of the proposed transaction, shareholders of icosavax will receive $15.00 in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, for.
2023-12-12 11:13:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Icosavax, Inc. Has Obtained A Fair Price In Its Transaction With Astrazeneca
Milwaukee , dec. 12, 2023 /prnewswire/ -- ademi llp is investigating icosavax (nasdaq: icvx) for possible breaches of fiduciary duty and other violations of law in its transaction with astrazeneca. click here to learn how to join the https://www.ademilaw.com/case/icosavax-inc or call guri ademi toll-free at 866-264-3995.
Latest News
2023-12-13 13:32:49 - Zacks Investment Research
Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know
Does Icosavax, Inc. (ICVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-12-13 13:32:36 - Zacks Investment Research
Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade
Icosavax, Inc. (ICVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-12-12 12:55:47 - Investopedia
Why AstraZeneca Is Buying Icosavax For $1.1 Billion
Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine technology.
2023-12-12 08:07:31 - InvestorPlace
Why Is Icosavax (ICVX) Stock Up 46% Today?
Icosavax (NASDAQ: ICVX ) stock is rising higher on Tuesday after announcing a major acquisition deal with AstraZeneca (NASDAQ: AZN ). According to a press release, AstraZeneca is acquiring Icosavax for $15 per share.
2023-12-12 07:03:34 - Proactive Investors
Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover
Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish pharma group AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) for $838 million cash up front, potentially rising to $1.1 billion. Having closed at $10.51 yesterday, the stock jumped to $15.25 in pre-market trading this morning, above the offer price of $15.00 per share.
2023-12-12 04:29:32 - Forbes
AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-causing viruses.
2023-12-12 02:29:55 - Proactive Investors
AstraZeneca boosts RSV profile with $1.1bn Icosavax deal
AstraZeneca has bought US biopharmaceutical company, Icosavax Inc, for up to $1.1 billion. The Anglo-Swedish drugs maker said the deal will build on its expertise in respiratory syncytial virus (RSV), and strengthen its Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12.
2023-12-12 02:16:11 - Reuters
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.
2023-12-08 11:16:25 - Zacks Investment Research
Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 175.9% in Icosavax, Inc. (ICVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-12-04 10:34:25 - Zacks Investment Research
Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable
Icosavax, Inc. (ICVX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.